Shaobo Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shaobo Yang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Fangdi Zhu
Department of Neurosurgery Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City) Changde Hunan China
1 shared publicationHao Dong
Department of Neurosurgery Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City) Changde Hunan China
1 shared publicationHu Zeng
Department of Neurosurgery, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde city), NO. 818 Renmin Road, Changde, Hunan, 415003, China
1 shared publication- Jie Zhao
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China
1 shared publication Jun Xia
Department of Neurosurgery, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde city), NO. 818 Renmin Road, Changde, Hunan, 415003, China
1 shared publicationMin Yuan
Department of Neurosurgery, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde city), NO. 818 Renmin Road, Changde, Hunan, 415003, China
1 shared publication
Latest Publications
- Open Access
- 3 June 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (6) , e70965
Association of Circulating Tumor DNA With Brain Metastases: A Systematic Review and Meta‐Analysis
Background: Brain metastases are a major contributor to morbidity and mortality in patients with advanced solid tumors; however, early detection and accurate prognostic assessment remain significant clinical challenges. ctDNA is a minimally invasive biomarker that allows real‐time monitoring of tumor behavior and provides information on systemic tumor burden and molecular diversity. This study aimed to systematically evaluate the diagnostic and prognostic value of ctDNA in brain metastases, with particular emphasis on the complementary roles of plasma and CSF ctDNA. Methods: PubMed, Embase, Cochrane Library, Web of Science, and ScienceDirect were systematically searched up to January 2025. Pooled ORs, SMDs, and HRs with 95% CIs were calculated using fixed‐effects or random‐effects models according to heterogeneity. Results: Fifteen studies ( N = 1763) were included. ctDNA positivity was significantly associated with increased risk of brain metastases (OR = 1.67, 95% CI: 1.24–2.26, p = 0.001). Subgroup analysis showed that NGS had notably higher predictive performance (OR = 5.50, 95% CI: 1.92–15.76, p = 0.002). Plasma ctDNA levels were significantly higher in patients with brain metastases (SMD = 0.51, 95% CI: 0.18–0.84, p = 0.002). Notably, CSF ctDNA positivity was strongly associated with worse overall survival (HR = 2.75, 95% CI: 1.75–4.32, p < 0.001). Conclusion: Plasma ctDNA serves as a non‐invasive biomarker for systemic metastatic risk, whereas CSF ctDNA provides superior prognostic value for intracranial disease. Using these biomarkers together in a clinical workflow could enhance risk assessment and guide treatment decisions in patients with brain metastases.
- 3 June 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (6) , e70965
Open AccessAssociation of Circulating Tumor DNA With Brain Metastases: A Systematic Review and Meta‐Analysis
Background: Brain metastases are a major contributor to morbidity and mortality in patients with advanced solid tumors; however, early detection and accurate prognostic assessment remain significant clinical challenges. ctDNA is a minimally invasive biomarker that allows real‐time monitoring of tumor behavior and provides information on systemic tumor burden and molecular diversity. This study aimed to systematically evaluate the diagnostic and prognostic value of ctDNA in brain metastases, with particular emphasis on the complementary roles of plasma and CSF ctDNA. Methods: PubMed, Embase, Cochrane Library, Web of Science, and ScienceDirect were systematically searched up to January 2025. Pooled ORs, SMDs, and HRs with 95% CIs were calculated using fixed‐effects or random‐effects models according to heterogeneity. Results: Fifteen studies ( N = 1763) were included. ctDNA positivity was significantly associated with increased risk of brain metastases (OR = 1.67, 95% CI: 1.24–2.26, p = 0.001). Subgroup analysis showed that NGS had notably higher predictive performance (OR = 5.50, 95% CI: 1.92–15.76, p = 0.002). Plasma ctDNA levels were significantly higher in patients with brain metastases (SMD = 0.51, 95% CI: 0.18–0.84, p = 0.002). Notably, CSF ctDNA positivity was strongly associated with worse overall survival (HR = 2.75, 95% CI: 1.75–4.32, p < 0.001). Conclusion: Plasma ctDNA serves as a non‐invasive biomarker for systemic metastatic risk, whereas CSF ctDNA provides superior prognostic value for intracranial disease. Using these biomarkers together in a clinical workflow could enhance risk assessment and guide treatment decisions in patients with brain metastases.
- 6 May 2025
- Published by Wolters Kluwer Health in Shock
- Vol. 64 (2) , 254-264
CO-CHAPERONE P23 INHIBITS FERROPTOSIS IN SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY BY REGULATING GPX4 STABILITY
Ferroptosis, an iron-dependent form of regulated cell death, has been implicated in severe kidney diseases, particularly those characterized by the depletion of GPX4. Despite its clinical significance, the molecular mechanisms driving GPX4 reduction in SA-AKI remain poorly understood. In this study, we uncover a novel regulatory axis involving the RNA-binding protein P23 and GPX4 mRNA stability in SA-AKI pathogenesis. Using integrated in vivo and in vitro models, we demonstrate that P23 expression is significantly upregulated during SA-AKI and functions as a critical suppressor of ferroptosis. Mechanistically, pharmacological inhibition of P23 with celastrol exacerbated renal dysfunction and amplified ferroptotic damage, as evidenced by elevated lipid peroxidation, iron overload, and GPX4 downregulation. Conversely, P23 overexpression robustly attenuated ferroptosis by stabilizing GPX4 mRNA, thereby preserving GPX4 protein levels and redox homeostasis. Crucially, RIP and Co-immunoprecipitation assays revealed that P23 directly binds to GPX4 mRNA and protein, forming a protective complex that impedes mRNA degradation and ferroptotic cascades. These findings establish P23 as a multifunctional regulator of ferroptosis and highlight its RNA-binding activity as a therapeutically targetable mechanism for mitigating SA-AKI. Our work provides a foundation for developing P23-centric interventions to combat ferroptosis-driven kidney injury in sepsis.
- 6 May 2025
- Published by Wolters Kluwer Health in Shock
- Vol. 64 (2) , 254-264
CO-CHAPERONE P23 INHIBITS FERROPTOSIS IN SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY BY REGULATING GPX4 STABILITY
Ferroptosis, an iron-dependent form of regulated cell death, has been implicated in severe kidney diseases, particularly those characterized by the depletion of GPX4. Despite its clinical significance, the molecular mechanisms driving GPX4 reduction in SA-AKI remain poorly understood. In this study, we uncover a novel regulatory axis involving the RNA-binding protein P23 and GPX4 mRNA stability in SA-AKI pathogenesis. Using integrated in vivo and in vitro models, we demonstrate that P23 expression is significantly upregulated during SA-AKI and functions as a critical suppressor of ferroptosis. Mechanistically, pharmacological inhibition of P23 with celastrol exacerbated renal dysfunction and amplified ferroptotic damage, as evidenced by elevated lipid peroxidation, iron overload, and GPX4 downregulation. Conversely, P23 overexpression robustly attenuated ferroptosis by stabilizing GPX4 mRNA, thereby preserving GPX4 protein levels and redox homeostasis. Crucially, RIP and Co-immunoprecipitation assays revealed that P23 directly binds to GPX4 mRNA and protein, forming a protective complex that impedes mRNA degradation and ferroptotic cascades. These findings establish P23 as a multifunctional regulator of ferroptosis and highlight its RNA-binding activity as a therapeutically targetable mechanism for mitigating SA-AKI. Our work provides a foundation for developing P23-centric interventions to combat ferroptosis-driven kidney injury in sepsis.
- 16 April 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 133, 112047
Relationship between chemokine/chemokine receptor and glioma prognosis and outcomes: Systematic review and meta-analysis
- 16 April 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 133, 112047
Relationship between chemokine/chemokine receptor and glioma prognosis and outcomes: Systematic review and meta-analysis